title: Augmentation of low ovarian response to superovulation before in vitro fertilization following priming with contraceptive pills.
abstract: Poor ovarian response to superovulation treatment is observed in a certain group of patients, the so-called 'low responders'. Despite the evolution of sophisticated controlled ovarian hyperstimulation (COH) regimens prior to the in vitro fertilization (IVF), the ideal stimulation protocol for the low responder has yet to be formulated. The objective of this study was to assess the effect of oral contraceptive pills (OCP), administered before the initiation of superovulation, on ovarian response and IVF treatment results in patients with previous 'low response' to exogenous gonadotropin stimulation. The study group comprised 42 patients who had exhibited poor ovarian response to standard superovulation protocols in at least two previous consecutive treatment attempts. Contraceptive pills were administered for 28-42 days and were immediately followed by menotropin treatment. The study group (n=50 cycles) was compared with the control group consisting of previous cycles (n=88) of the same women. Significant differences were noted in peak estradiol levels (983 +/- 739 vs. 517 +/- 249 pg/ml; P <0.01, paired Student's t test) and number of pre-ovulatory follicles between the study and the control groups. Thirty-three of the cycles (66%) reached the stage of ovum pick-up, compared with 22 (25%) of the previous IVF cycles in these women. The mean number of oocytes retrieved was 6.1 +/- 3.0 and 2.4 +/- 1.3 in the study and control groups, respectively (P <0.01; paired Student's t test). Embryo transfer (ET) was performed in 62% of the treatment cycles and resulted in five clinical pregnancies (16.1% per ET). No pregnancies were recorded in the control group. This study demonstrates the beneficial effect of OCP given prior to IVF treatment, and provides an efficient treatment modality for women who consistently respond poorly to standard COH protocols.
authors.affiliation: Infertility and IVF Unit, Department of Obstetrics and Gynecology, Rabin Medical Center, Petah Tikva, Israel.
authors.forename: B
authors.initials: B
authors.lastname: Fisch
authors.forename: M
authors.initials: M
authors.lastname: Royburt
authors.forename: H
authors.initials: H
authors.lastname: Pinkas
authors.forename: O M
authors.initials: OM
authors.lastname: Avrech
authors.forename: G A
authors.initials: GA
authors.lastname: Goldman
authors.forename: J
authors.initials: J
authors.lastname: Bar
authors.forename: Y
authors.initials: Y
authors.lastname: Tadir
authors.forename: J
authors.initials: J
authors.lastname: Ovadia
mesh_terms: D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood; D019304:Ethinyl Estradiol-Norgestrel Combination / Q000627:therapeutic use*; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use; D005307:Fertilization in Vitro; D006801:Humans; D008596:Menotropins / Q000627:therapeutic use; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D013480:Superovulation / Q000187:drug effects*; D017211:Treatment Failure
chemical_list: D003277:Contraceptives, Oral, Combined; D005300:Fertility Agents, Female; D004958:Estradiol; D008596:Menotropins; D019304:Ethinyl Estradiol-Norgestrel Combination